留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

叶酸在心脑血管疾病防治中的机遇与挑战

成彦琼 张浩 王威 顾小飞 刘爱军

成彦琼, 张浩, 王威, 顾小飞, 刘爱军. 叶酸在心脑血管疾病防治中的机遇与挑战[J]. 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
引用本文: 成彦琼, 张浩, 王威, 顾小飞, 刘爱军. 叶酸在心脑血管疾病防治中的机遇与挑战[J]. 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
CHENG Yan-qiong, ZHANG Hao, WANG Wei, GU Xiao-fei, LIU Ai-jun. New challenge of folic acid on prevention of cardiovascular and cerebrovascular diseases[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
Citation: CHENG Yan-qiong, ZHANG Hao, WANG Wei, GU Xiao-fei, LIU Ai-jun. New challenge of folic acid on prevention of cardiovascular and cerebrovascular diseases[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003

叶酸在心脑血管疾病防治中的机遇与挑战

doi: 10.3969/j.issn.1006-0111.2013.05.003
基金项目: 国家自然科学基金资助项目(81273505).

New challenge of folic acid on prevention of cardiovascular and cerebrovascular diseases

  • 摘要: 叶酸缺乏可导致高同型半胱氨酸血症,而高同型半胱氨酸血症是心脑血管疾病的独立危险因素。过去认为补充叶酸可降低体内同型半胱氨酸水平,从而预防心脑血管疾病的发生。但随着大量临床随机对照试验的进行,人们发现降低同型半胱氨酸血症并不能为心血管疾病患者带来益处,脑卒中方面的益处还需要更多临床数据证明。叶酸等B族维生素在心脑血管疾病的预防领域还存在着很大的挑战。笔者就目前叶酸等在心脑血管疾病中的应用现状及存在问题作一综述。
  • [1] Collaboration HLT.Lowering blood homocysteine with folic acid based supplements:meta-analysis of randomized trials [J].BMJ,1998,316(7135):894.
    [2] Selhub J,Jacques PF,Wilson PW,et al.Vitamin status and intake as primary determinants of homocysteinemia in an elderly population[J].JAMA,1993,270(22):2693.
    [3] NOStuart JM,Derek L,Ian FW,et al.Folate, homocysteine, endothelial function and cardiovascular disease[J].Cire Res,2000,87(5):840.
    [4] Gottsater A,Forsblad J,Mattiasson I,et al.Decreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocysteinemia[J].Int Angiol,2002,21(2):158.
    [5] McCully KS.Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis[J].Am J Pathol,1969,56 (1):111.
    [6] Wilcken DE,Wilcken B.The pathogenesis of coronary artery disease. A possible role for methionine metabolism[J].J Clin Invest,1976,57 (4):1079.
    [7] Ward M.Homocysteine,folate and cardiovascular disease[J].Int J Vitam Nutr Res,2001,71(3):173.
    [8] Homocysteine Lowering Trialists' Collaboration.Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials[J].Am J Clin Nutr, 2005,82(4):806.
    [9] Homocysteine Studies Collaboration.Homocysteine and risk of ischemic heart disease and stroke:a meta-analysis[J].JAMA,2002,288(16): 2015.
    [10] Kelly PJ,Rosand J,Kistler JP,et al.Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke:results of a meta-analysis[J].Neurology, 2002, 59(4):529.
    [11] Lewis SJ,Ebrahim S,Davey Smith G.Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease:does totality of evidence support causal role for homocysteine and preventive potential of folate[J].BMJ, 2005,331(7524):1053.
    [12] Sarkar PK, Lambert LA. Aetiology and treatment of hyperhomocysteinaemia causing ischaemic stroke[J].Int J Clin Pract,2001,55(4):262.
    [13] Oncel C,Demir S,Güler S,et al.Association between cholesterols,homocysteine and silent brain infarcts[J].Intern Med J,2009,39(3):150.
    [14] Homocysteine Lowering Trialists' Collaboration.Dose-dependent effects of folic acid on blood concentrations of homocysteine:A meta-analysis of the randomized trials[J].Am J Clin Nutr.2005,82(4): 806.
    [15] Fallon UB,Virtamo J,Young I,et al.Homocysteine and cerebral infarction in finnish male smokers[J].Stroke,2003,34(6):280.
    [16] Liu AJ,Guo JM,Xia WL,et al.The new strategies for the prevention of stroke[J].Clin Exp Pharmacol Physiol,2009,37(2):265.
    [17] Sánchez-Moreno C,Jiménez-Escrig A, Martín A.Stroke:roles of B vitamins,homocysteine and antioxidants[J].Nutr Res Rev,2009,22(1):49.
    [18] Woo KS,Chook P,Chan LL, et al. Long-term improvement in homocystein levels and arterial endothelial function after 1-year folic acid supplementation[J].Am J Med,2002,112(7):535.
    [19] Title IM,Cummings PM,Giddens K,et al.Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease[J].J Am Coll Cardiol,2000,36(3):758.
    [20] Chambers JC,Ueland PM,Obeid OA,et al.Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine[J].Circulation,2000,102(20):2479.
    [21] Lonn E,Yusuf S,Arnold MJ.Homocysteine Lowering with folic acid and B vitamins in vascular disease[J].N Engl J Med,2006,54(15):1567.
    [22] SEARCH Study Collaborative Group,Bowman L,Armitage J,et al.Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12 064 myocardial infarction survivors[J].Am Heart J,2007,154(5):815.
    [23] Ebbing M,Bleie O,Ueland PM,et al.Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography:a randomized controlled trial[J].JAMA,2008,300(7):795.
    [24] Albert CM,Cook NR,Gaziano JM,et al.Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial[J].JAMA, 2008,299(17):2027.
    [25] Bφnaa KH, Njφlstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction[J].N Engl J Med, 2006, 354(15):1578.
    [26] Wrone EM, Hornberger JM,Zehnder JL,et al.Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease[J].J Am Soc Nephrol,2004,15(2):420.
    [27] Liem AH,van Boven AJ,Veeger NJ,et al.Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction:a randomized pilot trial[J].Int J Cardiol,2004,93(2-3):175.
    [28] Zoungas S,McGrath BP,Branley P,et al.Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial[J].J Am Coll Cardiol 2006,47(6):1108.
    [29] Bazzano LA,Reynolds K,Holder KN,et al.Effect of folic acid supplementation on risk of cardiovascular diseases:a meta-analysis of randomized controlled trials[J].JAMA,2006,296(22):2720.
    [30] Martí-Carvajal AJ,Solà I,Lathyris D,et al. Homocysteine lowering interventions for preventing cardiovascular events[J].Cochrane Database Syst Rev. 2009, (4): CD006612.
    [31] Yang Q,Botto LD,Erickson JD,et al. Improvement in stroke mortality in Canada and the United States,1990 to 2002[J].Circulation,2006,113(10):1335.
    [32] Wang X,Qin X,Demirtas H,et al.Efficacy of folic acid supplementation in stroke prevention:a meta-analysis[J].Lancet,2007;369(9576): 1876.
    [33] Spence JD.Homocysteine-lowering therapy:a role in stroke prevention[J]. Lancet Neurol,2007,6(9):830.
    [34] Antoniades C,Antonopoulos AS,Tousoulis D,et al. Homocysteine and coronary atherosclerosis:from folate fortification to the recent clinical trials[J]. Eur Heart J,2009,30(1):6.
  • [1] 何晓莉, 施艺玮, 陈兰, 刘悦, 洪战英.  基于心血管芯片模型的4种深海毒素致伤评价与雷公藤甲素的保护作用研究 . 药学实践与服务, 2023, 41(3): 149-154, 159. doi: 10.12206/j.issn.2097-2024.202206018
    [2] 青胜利, 王淑娜, 汪东昇, 吕小群, 徐添颖, 缪朝玉.  肝脏特异性Nampt基因敲除对缺血性脑卒中的影响 . 药学实践与服务, 2022, 40(1): 12-19. doi: 10.12206/j.issn.1006-0111.202107068
    [3] 王辉, 李歆, 陈敬.  试点城市带量采购政策对某三级综合医院门诊心血管类原研药和仿制药利用状况的影响 . 药学实践与服务, 2020, 38(4): 373-378. doi: 10.12206/j.issn.1006-0111.202001054
    [4] 张莉燕, 宋金春.  “质量源于设计”在制备N-乙酰半胱氨酸注射液中的应用 . 药学实践与服务, 2019, 37(6): 552-558. doi: 10.3969/j.issn.1006-0111.2019.06.016
    [5] 沈启睿, 李永华, 张文杰, 王培.  同型半胱氨酸激活JNK信号通路诱导血管平滑肌细胞氧化应激的损伤研究 . 药学实践与服务, 2018, 36(6): 499-502,511. doi: 10.3969/j.issn.1006-0111.2018.06.005
    [6] 沈玲玲, 应茵, 陆绪亮, 宋洪涛, 戴海斌.  长期丙戊酸钠单药治疗癫痫致高同型半胱氨酸血症1例 . 药学实践与服务, 2017, 35(4): 383-384. doi: 10.3969/j.issn.1006-0111.2017.04.024
    [7] 刘纯, 杨晓晨, 陈伯文, 尚尔宁.  重症脑卒中患者营养风险筛查与营养支持现状调查 . 药学实践与服务, 2016, 34(5): 408-411. doi: 10.3969/j.issn.1006-0111.2016.05.007
    [8] 焦育强, 刘文斌, 袁夏, 姜玉, 田霖, 金磊, 张川.  丹参素及其衍生物心血管作用机制的研究进展 . 药学实践与服务, 2015, 33(5): 389-391,405. doi: 10.3969/j.issn.1006-0111.2015.05.002
    [9] 李倩, 芮耀诚.  Lox-1—心血管疾病防治的新靶标 . 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
    [10] 范志雄, 谢和辉.  抑郁症的药物治疗进展 . 药学实践与服务, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
    [11] 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉.  "Polypill"的发展及前景 . 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
    [12] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [13] 路绪文, 刘晋华, 陈静然.  黄芪与心血管疾病 . 药学实践与服务, 2002, (1): 3-6.
    [14] 张黎, 芮耀诚.  内皮素受体拮抗剂在心血管病临床应用的可能性 . 药学实践与服务, 1997, (6): 340-344.
    [15] 赵士玫.  维生素B1、B12治疗舌炎的新用途 . 药学实践与服务, 1992, (1): 21-21.
    [16] 汤海峰, 姜远英.  血栓素A2受体拮抗剂防治心血管疾病的研究进展 . 药学实践与服务, 1992, (2): 7-11.
    [17] 张沂, 孙忠实.  阿司匹林在心血管疾病中应用的进展 . 药学实践与服务, 1990, (1): 19-22.
    [18] J.Pourchaire.  镁和心血管病理学 . 药学实践与服务, 1987, (4): 3-5.
    [19] DavidG.Lambie.  药物和叶酸盐代谢 . 药学实践与服务, 1986, (4): 21-22.
    [20] JRVane.  前列腺素类与心血管系统 . 药学实践与服务, 1984, (3): 6-9.
  • 加载中
计量
  • 文章访问数:  2111
  • HTML全文浏览量:  257
  • PDF下载量:  254
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-12-14
  • 修回日期:  2013-04-08

叶酸在心脑血管疾病防治中的机遇与挑战

doi: 10.3969/j.issn.1006-0111.2013.05.003
    基金项目:  国家自然科学基金资助项目(81273505).

摘要: 叶酸缺乏可导致高同型半胱氨酸血症,而高同型半胱氨酸血症是心脑血管疾病的独立危险因素。过去认为补充叶酸可降低体内同型半胱氨酸水平,从而预防心脑血管疾病的发生。但随着大量临床随机对照试验的进行,人们发现降低同型半胱氨酸血症并不能为心血管疾病患者带来益处,脑卒中方面的益处还需要更多临床数据证明。叶酸等B族维生素在心脑血管疾病的预防领域还存在着很大的挑战。笔者就目前叶酸等在心脑血管疾病中的应用现状及存在问题作一综述。

English Abstract

成彦琼, 张浩, 王威, 顾小飞, 刘爱军. 叶酸在心脑血管疾病防治中的机遇与挑战[J]. 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
引用本文: 成彦琼, 张浩, 王威, 顾小飞, 刘爱军. 叶酸在心脑血管疾病防治中的机遇与挑战[J]. 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
CHENG Yan-qiong, ZHANG Hao, WANG Wei, GU Xiao-fei, LIU Ai-jun. New challenge of folic acid on prevention of cardiovascular and cerebrovascular diseases[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
Citation: CHENG Yan-qiong, ZHANG Hao, WANG Wei, GU Xiao-fei, LIU Ai-jun. New challenge of folic acid on prevention of cardiovascular and cerebrovascular diseases[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
参考文献 (34)

目录

    /

    返回文章
    返回